Results 171 to 180 of about 205,719 (255)

Pan-cancer analysis of cholesterol metabolism reveals the uptake as a modulator of tumor immune features and of the KRAS pathway. [PDF]

Cell Oncol (Dordr)
Machado AL, Pinto A, Carvalho J, Fernandes V, Pereira L, Roelands J, Gonçalves J, Miranda NFCC, Oliveira MJ, Velho S.   +9 more
europepmc   +1 more source

Dinarski kras: Plitvi kras Zgornje Pivke

, 2018
openaire   +1 more source

Identification of KRAS mutation in rectal cancer based on a 2.5D deep learning model. [PDF]

Front Oncol
Zhang C, Li J, Chen P, Zhou Y, Shen J, Chen G.   +5 more
europepmc   +1 more source

KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We've All Been Waiting For. [PDF]

Clin Cancer Res
Stanger BZ, Vonderheide RH.
europepmc   +1 more source

Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series. [PDF]

Front Med (Lausanne)
Su Y, Wang C, Sun L, Jin F, Wang X, Wang S, Wang F.   +6 more
europepmc   +1 more source

Novel function of GTPBP2 in promoting hepatocellular carcinoma progression through inhibition of BTRC-mediated KRAS degradation. [PDF]

Cancer Cell Int
Huang PS, Chi HC, Lin YH, Huang WC, Liao WT, Wang PY, Wang LY, Wang YW, Lin TK, Liao CJ, Chang CJ, Lay IS, Yeh CT, Wang LH, Lin KH.   +14 more
europepmc   +1 more source

KRAS-elicited PDIA6 blocks PERK-dependent immunogenic cell death in pancreatic carcinoma. [PDF]

Oncoimmunology
Zhao L, Liu P, Kroemer G, Kepp O.
europepmc   +1 more source

The relationship between genetic mutations and organ metastasis in non-small cell lung cancer. [PDF]

Ther Adv Med Oncol
Xue H, Chen Y, Qi F, Chen K, Liu X, Zhang M, Gao Z, Cai S, Gao T, Zhang T.   +9 more
europepmc   +1 more source